查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1442900

基因傳遞系統市場（傳遞系統：病毒基因傳遞、非病毒基因傳遞和組合混合傳遞）- 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Gene Delivery System Market (Delivery System: Viral Gene Delivery, Non-viral Gene Delivery, and Combined Hybrid Delivery) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 222 Pages | 商品交期: 2-10個工作天內

價格

基因傳遞系統市場 - 報告範圍

TMR 關於與阿茲海默症相關的全球失智症市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2023 年至2031 年預測期內市場指標的寶貴見解。該報告提供了全球失智症的收入與 2017-2031 年期間阿茲海默症市場相關，考慮 2023 年為基準年，2031 年為預測年。該報告還提供了2023年至2031年全球與阿茲海默症相關的失智症市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解與阿茲海默症相關的失智症市場。

該報告深入研究了與阿茲海默症相關的全球失智症市場的競爭格局。與阿茲海默症相關的全球失智症市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球失智症相關市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：按交付系統

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按交付系統，2017-2031
    • 病毒基因傳遞
      • 腺病毒載體
      • 慢病毒載體
      • 逆轉錄病毒載體
      • 腺相關病毒載體
      • 仙台病毒載體
      • 單純皰疹病毒載體
      • 其他
    • 非病毒基因傳遞
      • 天然有機化合物
      • 物理方法
      • 化學方法
    • 組合混合交付
  • 市場吸引力分析：按交付系統

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2017-2031
    • 傳染性疾病
    • 腫瘤學
    • 眼科
    • 泌尿科
    • 糖尿病
    • 中樞神經系統
    • 其他
  • 市場吸引力分析：按應用

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2017-2031
    • 口服
    • 可注射
    • 吸入
    • 經皮
    • 眼睛
    • 鼻腔
    • 專題
  • 市場吸引力分析：按應用

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Novartis AG
    • Amgen Inc.
    • Oxford Biomedica PLC
    • Sibiono GeneTech Co., Ltd.
    • Shanghai Sunway Biotech Co., Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Johnson & Johnson Services, Inc.
    • Human Stem Cells Institute
Product Code: TMRGL41636

Gene Delivery System Market - Scope of Report

TMR's report on the global dementia associated with Alzheimer's disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer's disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer's disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer's disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer's disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer's disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer's disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer's disease market. Key players operating in the global dementia associated with Alzheimer's disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer's disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer's disease Market Report:

  • What is the sales/revenue generated by dementia associated with Alzheimer's disease across all regions during the forecast period?
  • What are the opportunities in the global dementia associated with Alzheimer's disease market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Gene Delivery System Market - Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer's disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer's disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer's disease market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gene Delivery System Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Gene Delivery System Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Gene Delivery System Market Analysis and Forecast, by Delivery System

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Delivery System, 2017-2031
    • 6.3.1. Viral Gene Delivery
      • 6.3.1.1. Adenovirus Vector
      • 6.3.1.2. Lentivirus Vector
      • 6.3.1.3. Retrovirus Vector
      • 6.3.1.4. Adeno-associated Virus Vector
      • 6.3.1.5. Sendai Virus Vector
      • 6.3.1.6. Herpes Simplex Virus Vector
      • 6.3.1.7. Others
    • 6.3.2. Non-viral Gene Delivery
      • 6.3.2.1. Natural Organic Compounds
      • 6.3.2.2. Physical Methods
      • 6.3.2.3. Chemical Methods
    • 6.3.3. Combined Hybrid Delivery
  • 6.4. Market Attractiveness Analysis, by Delivery System

7. Global Gene Delivery System Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Infectious Diseases
    • 7.3.2. Oncology
    • 7.3.3. Ophthalmology
    • 7.3.4. Urology
    • 7.3.5. Diabetes
    • 7.3.6. CNS
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Gene Delivery System Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Injectable
    • 8.3.3. Inhalation
    • 8.3.4. Transdermal
    • 8.3.5. Ocular
    • 8.3.6. Nasal
    • 8.3.7. Topical
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Gene Delivery System Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Gene Delivery System Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Delivery System, 2017-2031
    • 10.3.1. Viral Gene Delivery
      • 10.3.1.1. Adenovirus Vector
      • 10.3.1.2. Lentivirus Vector
      • 10.3.1.3. Retrovirus Vector
      • 10.3.1.4. Adeno-associated Virus Vector
      • 10.3.1.5. Sendai Virus Vector
      • 10.3.1.6. Herpes Simplex Virus Vector
      • 10.3.1.7. Others
    • 10.3.2. Non-viral Gene Delivery
      • 10.3.2.1. Natural Organic Compounds
      • 10.3.2.2. Physical Methods
      • 10.3.2.3. Chemical Methods
      • 10.3.2.4. Acute Dialysis Products
    • 10.3.3. Combined Hybrid Delivery
  • 10.4. Market Value Forecast, by Application, 2017-2031
    • 10.4.1. Infectious Diseases
    • 10.4.2. Oncology
    • 10.4.3. Ophthalmology
    • 10.4.4. Urology
    • 10.4.5. Diabetes
    • 10.4.6. CNS
    • 10.4.7. Others
  • 10.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.5.1. Oral
    • 10.5.2. Injectable
    • 10.5.3. Inhalation
    • 10.5.4. Transdermal
    • 10.5.5. Ocular
    • 10.5.6. Nasal
    • 10.5.7. Topical
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Delivery System
    • 10.7.2. By Application
    • 10.7.3. By Route of Administration
    • 10.7.4. By Country

11. Europe Gene Delivery System Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Delivery System, 2017-2031
    • 11.3.1. Viral Gene Delivery
      • 11.3.1.1. Adenovirus Vector
      • 11.3.1.2. Lentivirus Vector
      • 11.3.1.3. Retrovirus Vector
      • 11.3.1.4. Adeno-associated Virus Vector
      • 11.3.1.5. Sendai Virus Vector
      • 11.3.1.6. Herpes Simplex Virus Vector
      • 11.3.1.7. Others
    • 11.3.2. Non-viral Gene Delivery
      • 11.3.2.1. Natural Organic Compounds
      • 11.3.2.2. Physical Methods
      • 11.3.2.3. Chemical Methods
      • 11.3.2.4. Acute Dialysis Products
    • 11.3.3. Combined Hybrid Delivery
  • 11.4. Market Value Forecast, by Application, 2017-2031
    • 11.4.1. Infectious Diseases
    • 11.4.2. Oncology
    • 11.4.3. Ophthalmology
    • 11.4.4. Urology
    • 11.4.5. Diabetes
    • 11.4.6. CNS
    • 11.4.7. Others
  • 11.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.5.1. Oral
    • 11.5.2. Injectable
    • 11.5.3. Inhalation
    • 11.5.4. Transdermal
    • 11.5.5. Ocular
    • 11.5.6. Nasal
    • 11.5.7. Topical
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Delivery System
    • 11.7.2. By Application
    • 11.7.3. By Route of Administration
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Gene Delivery System Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Delivery System, 2017-2031
    • 12.3.1. Viral Gene Delivery
      • 12.3.1.1. Adenovirus Vector
      • 12.3.1.2. Lentivirus Vector
      • 12.3.1.3. Retrovirus Vector
      • 12.3.1.4. Adeno-associated Virus Vector
      • 12.3.1.5. Sendai Virus Vector
      • 12.3.1.6. Herpes Simplex Virus Vector
      • 12.3.1.7. Others
    • 12.3.2. Non-viral Gene Delivery
      • 12.3.2.1. Natural Organic Compounds
      • 12.3.2.2. Physical Methods
      • 12.3.2.3. Chemical Methods
      • 12.3.2.4. Acute Dialysis Products
    • 12.3.3. Combined Hybrid Delivery
  • 12.4. Market Value Forecast, by Application, 2017-2031
    • 12.4.1. Infectious Diseases
    • 12.4.2. Oncology
    • 12.4.3. Ophthalmology
    • 12.4.4. Urology
    • 12.4.5. Diabetes
    • 12.4.6. CNS
    • 12.4.7. Others
  • 12.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.5.1. Oral
    • 12.5.2. Injectable
    • 12.5.3. Inhalation
    • 12.5.4. Transdermal
    • 12.5.5. Ocular
    • 12.5.6. Nasal
    • 12.5.7. Topical
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Delivery System
    • 12.7.2. By Application
    • 12.7.3. By Route of Administration
    • 12.7.4. By Country/Sub-region

13. Latin America Gene Delivery System Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Delivery System, 2017-2031
    • 13.3.1. Viral Gene Delivery
      • 13.3.1.1. Adenovirus Vector
      • 13.3.1.2. Lentivirus Vector
      • 13.3.1.3. Retrovirus Vector
      • 13.3.1.4. Adeno-associated Virus Vector
      • 13.3.1.5. Sendai Virus Vector
      • 13.3.1.6. Herpes Simplex Virus Vector
      • 13.3.1.7. Others
    • 13.3.2. Non-viral Gene Delivery
      • 13.3.2.1. Natural Organic Compounds
      • 13.3.2.2. Physical Methods
      • 13.3.2.3. Chemical Methods
      • 13.3.2.4. Acute Dialysis Products
    • 13.3.3. Combined Hybrid Delivery
  • 13.4. Market Value Forecast, by Application, 2017-2031
    • 13.4.1. Infectious Diseases
    • 13.4.2. Oncology
    • 13.4.3. Ophthalmology
    • 13.4.4. Urology
    • 13.4.5. Diabetes
    • 13.4.6. CNS
    • 13.4.7. Others
  • 13.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.5.1. Oral
    • 13.5.2. Injectable
    • 13.5.3. Inhalation
    • 13.5.4. Transdermal
    • 13.5.5. Ocular
    • 13.5.6. Nasal
    • 13.5.7. Topical
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Delivery System
    • 13.7.2. By Application
    • 13.7.3. By Route of Administration
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Gene Delivery System Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Delivery System, 2017-2031
    • 14.3.1. Viral Gene Delivery
      • 14.3.1.1. Adenovirus Vector
      • 14.3.1.2. Lentivirus Vector
      • 14.3.1.3. Retrovirus Vector
      • 14.3.1.4. Adeno-associated Virus Vector
      • 14.3.1.5. Sendai Virus Vector
      • 14.3.1.6. Herpes Simplex Virus Vector
      • 14.3.1.7. Others
    • 14.3.2. Non-viral Gene Delivery
      • 14.3.2.1. Natural Organic Compounds
      • 14.3.2.2. Physical Methods
      • 14.3.2.3. Chemical Methods
      • 14.3.2.4. Acute Dialysis Products
    • 14.3.3. Combined Hybrid Delivery
  • 14.4. Market Value Forecast, by Application, 2017-2031
    • 14.4.1. Infectious Diseases
    • 14.4.2. Oncology
    • 14.4.3. Ophthalmology
    • 14.4.4. Urology
    • 14.4.5. Diabetes
    • 14.4.6. CNS
    • 14.4.7. Others
  • 14.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.5.1. Oral
    • 14.5.2. Injectable
    • 14.5.3. Inhalation
    • 14.5.4. Transdermal
    • 14.5.5. Ocular
    • 14.5.6. Nasal
    • 14.5.7. Topical
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Delivery System
    • 14.7.2. By Application
    • 14.7.3. By Route of Administration
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Oxford Biomedica PLC
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sibiono GeneTech Co., Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Pfizer, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Bayer AG
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Johnson & Johnson Services, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Human Stem Cells Institute
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 02: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 07: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 11: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 13: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 15: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 17: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 19: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 21: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 23: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

List of Figures

  • Figure 01: Global Gene Delivery System Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Gene Delivery System Market Revenue (US$ Mn), by Delivery System, 2022
  • Figure 03: Global Gene Delivery System Market Value Share, by Delivery System, 2022
  • Figure 04: Global Gene Delivery System Market Revenue (US$ Mn), by Application, 2022
  • Figure 05: Global Gene Delivery System Market Value Share, by Application, 2022
  • Figure 06: Global Gene Delivery System Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 07: Global Gene Delivery System Market Value Share, by Route of Administration, 2022
  • Figure 08: Global Gene Delivery System Market Value Share, by Region, 2022
  • Figure 09: Global Gene Delivery System Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 11: Global Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 12: Global Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 13: Global Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 14: Global Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 15: Global Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 16: Global Gene Delivery System Market Value Share Analysis, by Region, 2022-2031
  • Figure 17: Global Gene Delivery System Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Gene Delivery System Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Gene Delivery System Market Value Share Analysis, by Country, 2022-2031
  • Figure 21: North America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 22: North America Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 23: North America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 24: North America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 25: North America Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 26: North America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 27: Europe Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Europe Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 31: Europe Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 32: Europe Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 33: Europe Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 34: Europe Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 35: Europe Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 36: Asia Pacific Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 39: Asia Pacific Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 40: Asia Pacific Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 41: Asia Pacific Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 42: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 43: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 44: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 45: Latin America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 48: Latin America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 49: Latin America Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 50: Latin America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 51: Latin America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 52: Latin America Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 53: Latin America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 54: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Delivery System, 2022-2031
  • Figure 58: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Application, 2022-2031
  • Figure 59: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 60: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 61: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 62: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023-2031